CZ20033476A3 - Protilátky specifické pro CD@@v - Google Patents

Protilátky specifické pro CD@@v Download PDF

Info

Publication number
CZ20033476A3
CZ20033476A3 CZ20033476A CZ20033476A CZ20033476A3 CZ 20033476 A3 CZ20033476 A3 CZ 20033476A3 CZ 20033476 A CZ20033476 A CZ 20033476A CZ 20033476 A CZ20033476 A CZ 20033476A CZ 20033476 A3 CZ20033476 A3 CZ 20033476A3
Authority
CZ
Czechia
Prior art keywords
seq
acid sequence
antibody
nucleic acid
variant
Prior art date
Application number
CZ20033476A
Other languages
Czech (cs)
English (en)
Inventor
Adolfágünther
Ostermannáelinborg
Patzeltáerik
Sprollámarlies
Heiderákarl@Heinz
Migliettaájohnáj
Vanádongenáaugustinusáantoniusámariaásilvester
Original Assignee
Boehringeráingelheimáinternationalágmbh
Boehringeráingelheimápharmaceuticalsáinc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringeráingelheimáinternationalágmbh, Boehringeráingelheimápharmaceuticalsáinc filed Critical Boehringeráingelheimáinternationalágmbh
Publication of CZ20033476A3 publication Critical patent/CZ20033476A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CZ20033476A 2001-05-18 2002-05-17 Protilátky specifické pro CD@@v CZ20033476A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
CZ20033476A3 true CZ20033476A3 (cs) 2004-05-12

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20033476A CZ20033476A3 (cs) 2001-05-18 2002-05-17 Protilátky specifické pro CD@@v

Country Status (18)

Country Link
EP (1) EP1397387A1 (enExample)
JP (1) JP2005504517A (enExample)
CN (1) CN1541226A (enExample)
AR (1) AR036154A1 (enExample)
BR (1) BR0210905A (enExample)
CA (1) CA2443437A1 (enExample)
CZ (1) CZ20033476A3 (enExample)
EA (1) EA200301169A1 (enExample)
EC (1) ECSP034838A (enExample)
EE (1) EE200300569A (enExample)
HU (1) HUP0400030A3 (enExample)
MX (1) MXPA03010523A (enExample)
PE (1) PE20021098A1 (enExample)
PL (1) PL365735A1 (enExample)
SK (1) SK15592003A3 (enExample)
WO (1) WO2002094879A1 (enExample)
YU (1) YU91403A (enExample)
ZA (1) ZA200307365B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
DK2167038T3 (en) * 2007-06-13 2018-08-06 Zymogenetics Inc USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2011212485B2 (en) 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
EA200301169A1 (ru) 2004-06-24
CN1541226A (zh) 2004-10-27
PE20021098A1 (es) 2003-02-11
EE200300569A (et) 2004-04-15
YU91403A (sh) 2006-05-25
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
WO2002094879A1 (en) 2002-11-28
MXPA03010523A (es) 2004-07-01
ECSP034838A (es) 2003-12-24
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
HUP0400030A3 (en) 2006-02-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
SK15592003A3 (sk) 2004-06-08
JP2005504517A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
CZ20033476A3 (cs) Protilátky specifické pro CD@@v
AU2017268399B2 (en) mRNA combination therapy for the treatment of cancer
KR102697797B1 (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
AU2025204314A1 (en) Improving the efficacy and safety of adoptive cellular therapies
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US7919606B2 (en) Biological products
KR100473836B1 (ko) 천연 인간형화 항체
KR100655979B1 (ko) 임파구계 종양의 치료제
AU2020203990A1 (en) Chimeric receptors and methods of use thereof
US20050214212A1 (en) Antibodies specific for CD44v6
EA013677B1 (ru) Человеческие моноклональные антитела против cd25 и их применение
CN104402998A (zh) 分离的抗体
JPH09506507A (ja) Ｃａ５５．１抗原指向性結合構造
CN111867626A (zh) 治疗淀粉样蛋白沉积疾病的方法和组合物
US20020150559A1 (en) Induction of T cell tolerance with CD40/B7 antagonists
NO301075B1 (no) Antistoff som er selektive for TAG-72 for diagnostisk bruk, DNA-sekvens som koder for det, ekspresjonsbærer og celle som kan uttrykke det samt blanding som omfatter antistoffet
ES2234099T3 (es) Anticuerpos monoclanales humanizados anti-alfa beta 3.
PT96509A (pt) Anticorpos recombinantes humanos anti-cd18
BRPI0609655A2 (pt) anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
KR20060022646A (ko) Ｓｔｏｐ-1 관련 조성물 및 방법
US20040258616A1 (en) Compositions and methods for treating cancer using IGSF9 and LIV-1
US20020086812A1 (en) Methods and compositions for diagnosis and treatment of cancer
KR20000075732A (ko) 임파구의 활성화 억제제
CN115335396A (zh) 靶向cd33的嵌合抗原受体
US20230391873A1 (en) Methods for treating mismatch repair deficient locally advanced rectal cancer using dostarlimab